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Abstract
Blood culture is the primary diagnostic test performed in a suspicion of bloodstream infection
to detect the presence of microorganisms and direct the treatment. However, blood culture
is slow and time consuming method to detect blood stream infections or separate septic
and/or bacteremic patients from others with less serious febrile disease. Plasma proteo-
mics, despite its challenges, remains an important source for early biomarkers for systemic
diseases and might show changes before direct evidence from bacteria can be obtained.
We have performed a plasma proteomic analysis, simultaneously at the time of blood cul-
ture sampling from ten blood culture positive and ten blood culture negative patients, and
quantified 172 proteins with two or more unique peptides. Principal components analysis,
Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) and ROC
curve analysis were performed to select protein(s) features which can classify the two
groups of samples. We propose a number of candidates which qualify as potential biomark-
ers to select the blood culture positive cases from negative ones. Pathway analysis by two
methods revealed complement activation, phagocytosis pathway and alterations in lipid
metabolism as enriched pathways which are relevant for the condition. Data are available
via ProteomeXchange with identifier PXD005022.
1. Introduction
Blood culture is a primary test to reveal the infection etiology in a febrile patient with a suspi-
cion of serious infection and to give important information on the need and quality of antibi-
otic treatment. However, in most cases, it takes more than 24 hours to reveal a positive finding
in blood culture and treatment must be initiated empirically. Depending on the criteria used
for taking blood culture, it is positive in less than 10% or maximally in about one third of cases
[1, 2]. Biomarkers such as PCT (procalcitonin), CRP (C-reactive protein) and sTREM (soluble
PLOS ONE | DOI:10.1371/journal.pone.0172987 February 24, 2017 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Kuusela P, Saraswat M, Joenva¨a¨ra¨ S,
Kaartinen J, Ja¨rvinen A, Renkonen R (2017)
Changes in plasma protein levels as an early
indication of a bloodstream infection. PLoS ONE 12
(2): e0172987. doi:10.1371/journal.pone.0172987
Editor: Aleksandra Nita-Lazar, NIH, UNITED
STATES
Received: September 28, 2016
Accepted: February 13, 2017
Published: February 24, 2017
Copyright: © 2017 Kuusela et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The raw files were
converted with MSConvert (ProteoWizard) to
mzML-files. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with
the dataset identifier PXD005022.
Funding: RR received the funding in the form of
grants TYH2013346 and TYH2016247 from
Helsinki University Hospital. The funders had no
role in the study design, data collection and
analysis, decision to publish or preparation of the
manuscript.
triggering receptor expressed on myeloid cells) are shown to be sensitive predictors of bacter-
emia (Bloodstream infection) [3–5]. However, they may be elevated in less serious infections
or systemic inflammatory responses due to other causes than a blood stream infection. The
problems to discern patients with a blood stream infection from those with a serious systemic
inflammatory response due to other causes like trauma or inflammation led to definition of
criteria for systemic inflammatory response syndrome (SIRS) which have guided the treatment
and research of serious ill patients especially in intensive care units [6, 7]. Recently, these crite-
ria have been shown to be unable to find all patients with risk of fatal outcome [8]. It has been
shown that CRP is a good marker for bacteremia (Bloodstream infection) [9]. Currently, nei-
ther clinical diagnostic criteria nor biomarkers can reliably detect patients with a bloodstream
infection in a timely fashion that would enable major changes in treatment efforts.
Early appropriate antimicrobial therapy has been shown to be one of the most important
denominators of good prognosis in severe blood stream infections [10, 11]. Early recognition
of bloodstream infection might help in allocating antimicrobial and supportive treatment to
patients with most benefit of it. Genome based techniques have been shown to be more rapid
and even more sensitive in verifying bloodstream infection as compared to conventional cul-
ture [12–14]. Whereas positive results may be obtained even within 6 hours, these techniques
may only detect given species included into the diagnostic setup. Therefore, a biomarker that
would reliably and early discern cases with true blood culture positivity might be an additional
advantage in clinical practice.
In this paper we present pilot findings of an LC-MS analysis of plasma proteins simulta-
neous with blood culture sampling to categorize patients with a bloodstream infection positive
and negative blood culture. The decision to perform blood culture has been made on clinical
basis by the treating physician in a suspicion of a serious infection like endocarditis, bacter-
emic pneumonia or urosepsis. Twenty patients were recruited to the study, ten of which were
clearly blood culture positive for various bacterial species (details in methods) and ten who
were blood culture negative. Both group of patients presented at the clinics as febrile. The
basic aim is to find a novel marker for the patients in need of immediate antibiotic therapy.
We have quantified 172 proteins with two or more unique peptides. Various statistical/mathe-
matical analysis such as ANOVA, Principle component analysis (PCA), Orthogonal Projec-
tions to Latent Structures Discriminant Analysis (OPLS-DA) and ROC curve analysis were
performed to select proteins features which can classify the two groups of samples (blood-
stream infection positive and negative as found by blood culture).
2. Materials and methods
2.1 Reagents
For plasma preprocessing Pierce SwellGel Blue Albumin Removal Discs, Pierce Centrifuge col-
umns as well as Pierce C18 Spin Columns were purchased from Thermo Scientific (Rockform,
IL, USA). The solvents and high-purity HPLC reagents were purchased from Waters (Milford,
MA, USA). All other reagents were from Sigma-Aldrich (St. Louis, MO, USA).
2.2 Plasma samples
Blood samples were collected to lithium-heparin tubes from adult febrile patients (age 53–91,
median age 76) entering the emergency outpatient clinic of Peijas Hospital, Helsinki Univer-
sity Hospital (Vantaa, Finland) and who were, due to clinical signs, subjects for bacterial blood
culturing. Blood cultures were taken based on clinical suspicion of a serious infection both
from the cases and from the controls on the same grounds. This has now been emphasized in
introduction as well as in discussion. An approval for the study was received from the Ethics
Plasma protein profile changes in bloodstream infection
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Committee of Medical Sciences (HUS 169/13/01/2014) and a written informed consent was
obtained from all subjects at the time of plasma sample collection. This written informed con-
sent procedure was approved by the ethics committee. Blood samples (3–5 ml) were adjusted
to room temperature for 15 min. Subsequently, plasma was separated by centrifugation
(1200xg) for 10 minutes at room temperature. Plasma samples were stored at -70˚C until
tested at the same time. Blood culturing was performed by using BacT/ALERT1 FA Plus and
BacT/ALERT1 FN Plus blood culture bottles (BioMerieux, Durham, NC, USA) and BacT
ALERT 3D incubator (BioMerieux). Identification of bacteria in positive blood cultures was
done by Vitek MS MALDI-TOF instrument (bioMerieux).
2.3 Plasma treatment and protein digestion
The workflow as well as plasma treatment and protein digestion are described in detail by
Kontro et al. [15]. Briefly, after thawing of samples albumin was depleted by Pierce SwellGel
Blue Albumin removal discs according to the manufacturer’s instructions. Albumin depleted
plasma was assayed by BCA assay kit (Pierce, Thermo Scientific, Rockform, IL, USA) for the
total protein concentration. Albumin-depleted plasma corresponding to 350 μg of protein was
dried in speed vacuum system (Savant, Thermofisher). After dissolving the dried pellets in 6 M
urea and 100 mM Tris-HCl pH 7.4, reduction and alkylation were performed by incubating
samples first in 10 mM of DTT for 60 minutes at room temperature (RT) followed by incuba-
tion in 30 mM iodoacetamide for 60 minutes in the dark at RT. Finally, after consumption of
excess of iodoacetamide with 30 mM DTT (60 minutes at RT) samples were diluted 1:10 with
ultrapure water (Milli-Q, EMD Millipore corp.) water and digested with trypsin (1:50 w:w
trypsin to protein ratio) for 18 hours at +37˚C. Samples were cleaned by Pierce C18 columns
according to the manufactures protocol. For LC-MS-analysis 30μg of peptides were first dried
in SpeedVac, dissolved in 0.1% formic acid containing 12.5 femtomole Hi3 peptide mixture
(Waters) per μL and finally stored at -20˚C until analyzed.
2.4 Liquid Chromatography-Mass Spectrometry (LC-MS) and
quantification
2.4.1 UPLC-MS. Four μL samples, equivalent to ~1.4μg total protein, were injected to
nano Acquity UPLC (Ultra Performance Liquid Chromatography)—system (Waters Corpora-
tion, MA, USA). TRIZAIC nanoTile 85μm x 100 mm HSS-T3u wTRAP was used as separating
device prior to mass spectrometer. Samples were loaded, trapped and washed for two minutes
with 8.0 μL/min with 1% B. The analytical gradient used is as follows: 0–1 minutes 1% B, at 2
minutes 5% B, at 65 minutes 30% B, at 78 minutes 50% B, at 80 minutes 85% B, at 83 minutes
85% B, at 84 minutes 1% B and at 90 minutes 1% B with 450nL/min. Buffers were made to
UPLC-grade chemicals (Sigma-Aldrich, MO, USA); Buffer A: 0.1% formic acid in water and
Buffer B: 0.1% formic acid in acetonitrile.
The data was acquired in DIA (data independent acquisition) fashion using HDMSE-mode
with Synapt G2-S HDMS (Waters Corporation, MA, USA). HDMSE mode included Ion
mobility spectroscopy (IMS). The collected data range was 100–2000 m/z, scan time one sec-
ond, IMS wave velocity 650 m/s, collision energy was ramped in trap between 20 to 60 V. Cali-
bration was done with Glu1-Fibrinopeptide B MS2 fragments and as a lock mass,
Glu1-Fibrinopeptide B precursor ion was used during the runs. The samples were run as tripli-
cates and further analysis was done with, Progenesis QI for Proteomics–software (Nonlinear
Dynamics, Newcastle, UK).
2.4.2 Data analysis. The data analysis procedure has been previously described in details
[16]. Briefly, the raw files were imported to Progenesis QI for proteomics software (Nonlinear
Plasma protein profile changes in bloodstream infection
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Dynamics, Newcastle, UK) using lock mass correction with 785.8426 m/z, corresponding to
doubly charged Glu1-Fibrinopeptide B. Default parameters for peak picking and alignment
algorithm were used. The software facilitated the peptide identification with ProteinLynx
Global Server and label-free quantification [17]. The peptide identification was done against
Uniprot human FASTA sequences (UniprotKB Release 2015_09, 20205 sequence entries) with
(CLPB_ECOLI (P63285)), ClpB protein sequence inserted for label-free quantification. Modi-
fications used were as follows: fixed at cysteine (carbamidomethyl) and variable in methionine
(oxidation). Trypsin was used as digesting agent and one missed cleavage was allowed. Fully
tryptic cleavage specificity was used. Fragment and peptide error tolerances were set to auto
and FDR to less than 1%. One or more ion fragments per peptide, three or more fragments per
protein and two or more peptides per protein were required for ion matching. The identified
proteins are grouped as one according to parsimony principle and also peptides unique to the
protein are reported. Parsimony principle states that protein hits are reported as the minimum
set that accounts for all observable peptides. Progenesis QI for proteomics does not take a strict
parsimonious approach because of over-stringency as has been pointed out before [18]. How-
ever, for resolution of conflicts, if two proteins contain some common peptides, protein with
fewer peptides is subsumed into the protein with higher number of peptides which are a super-
set of the subsumed protein’s peptides. All relevant proteins are listed as a group under the
lead protein with greatest coverage or the highest score when the coverages of two or more
proteins are equal. Quantitation is performed using the lead identity peptide data. More details
about this approach can be accessed on the software website (www.nonlinear.com).
The proteins were considered different if they have a fold change 2 or more and an ANOVA
p-value 0.05 or less. The ANOVA calculation assumes that the conditions are independent and
applies the statistical test that assumes the means of the conditions are equal. The label-free pro-
tein quantitation was done with Hi-N method [17]. In every injection the sample contained also
50 fmol of six CLPB_ECOLI (P63285, ClpB protein) peptides (Hi3 E. coli Standard, Waters).
Hi3 peptides are used for normalizing the peptide abundancies and relative quantitation was
based on all the non-conflicting peptides found. The peptide ranking is done across all the runs.
The abundancies of the peptides are averaged to provide a signal to the protein. Workings of the
Progenesis softwares have been described in details on the software website (www.nonlinear.
com) and also in published literature [19].
Differences between controls and cases were evaluated with ANOVA on a protein-to-pro-
tein basis. Principle component analysis was done with Progenesis QI for proteomics. EZinfo
3.0 (Release date Dec 02, 2014, Umetrics, Sweden) is a separate statistical package that can be
used with Progenesis QI for proteomics. The data was imported into the EZinfo and super-
vised OPLS-DA modeling was performed which gave us the variance vs correlation plot
(S-Plot). Default parameters were used. Receiver operating characteristic (ROC) curve analysis
was also performed on some of the significantly different proteins predicted by S-Plot. Ana-
lyse-It program which works with Microsoft Excel was used for making ROC curves with all
the default parameters. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier
PXD005022.
2.5 Pathway analysis
Integrated Molecular Pathway Level Analysis (IMPaLA) was used for pathway over representa-
tion analysis by their web-based service. The method and rationale behind the approach has
been published previously [20]. The background set for IMPaLA analysis were all the proteins
entities in all the pathways present in the database (~12185 proteins). Ingenuity pathway
Plasma protein profile changes in bloodstream infection
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analysis (Ingenuity Systems, Redwood City, CA) was used for performing core analysis on the
proteomic dataset with default parameters of the software. The results (canonical pathways)
are presented in the results section as a figure. The background set for IPA analysis was com-
plete IPA knowledgebase.
3. Results
3.1 Metadata
Ten samples of blood culture positive men and women and ten blood culture negative age and
sex matched febrile patients serving as controls were used for the current study. All samples
and their technical replicates behaved similarly in terms of chromatographic performance and
alignment therefore no sample was excluded from analysis. Based on the blood culture results
subsequent to the sampling, patients were divided into two groups. One group was with a posi-
tive blood culture report (8 men, 2 women, “Cases”) and another was with negative blood cul-
ture report (10 age and sex matched “Controls”). Bacteria identified in blood cultures were
Escherichia coli (4 samples), Streptococcus pneumoniae (2 samples), coagulase-negative Staphy-
lococcus (2 samples), Staphylococcus epidermidis and Streptococcus viridans (1 sample each).
The plasma CRP levels of blood culture positive patients ranged from 12 mg/mL to 399 mg/
mL. The percent coefficient of variation was found to be 70.65% for the blood cuture positive
patients. Among the control patients who had negative blood cultures, four patients had no
infection verified and were not treated by antibiotics and their plasma C-reactive protein at the
time of blood culture sampling ranged 13–101 mg/L. Two patients had a pyelonephritis (CRP
125 and 225 mg/L). Four patients had a respiratory infection which was supposed to be of viral
origin but three of them received oral antibiotics (doxycycline, cephalexin or co-amoxyclavula-
nate) and their CRP levels ranged 16–101 mg/L.
3.2 Proteomic dataset
In all samples combined, 172 proteins were quantified with the criterion of at least two unique
peptides per protein (complete data in S1 Table). Maximum fold changes were 8.844 to 1
when the highest mean was set to blood culture positive and from 5.967 to 1.002 when the
highest mean was set to control samples. One protein (Apolipoprotein L2) was found in only
the case. Top ten most upregulated (Highest mean case) and down regulated proteins (highest
mean control) in blood culture positive samples are given in Table 1.
Fourteen proteins passed the cutoff of 0.05 value in ANOVA when the highest mean was
set to blood culture positive and 39 proteins passed this cutoff when the highest mean was set
to controls. ANOVA p values were one of the main criterions to establish the proteins different
in the two classes of samples and therefore the proteins having p values more than 0.05 are not
shown in Table 1. These proteins are not considered different despite having big fold changes.
The number of unique peptides found was from 2 for multiple proteins to 243 for Alpha-
2-macroglobulin. The minimum confidence score reported in the current study is 6.13 for
Casein kinase I isoform alpha and highest is 1491 for Alpha-2-macroglobulin. The complete
data is given in S1 Table.
3.3 Principal component analysis (PCA)
PCA determines the main axes of variations in a dataset, which is helpful in visualization of
samples coming from two or more classes. It becomes simpler to visually establish the differ-
ences between the classes in a PCA biplot. PCA biplot is presented in Fig 1, when two classes,
cases vs controls were used for the PCA. The top panel in PCA represents the condition when
Plasma protein profile changes in bloodstream infection
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all the proteins with two or more unique peptides were considered for PCA and lower panel is
when only proteins with fold change of 2 or more between case vs control and also having
ANOVA p value less than 0.05 were considered. It can be seen in the top panel that controls
are represented in a tight cluster on one side while blood culture positive samples are more
Table 1. Top 10 up- and downregulated proteins in plasma of ten patients with a positive blood culture (cases) and ten with a negative blood cul-
ture (controls) at the time point of blood culture sampling. The top proteins are according to the fold change in case versus controls. Only the proteins
having less than 0.05 ANOVA p values are shown. Peptide count is the total peptides found for corresponding proteins and unique peptides is the number of
unique peptides found out of the total peptides. Confidence score, ANOVA p value, maximum fold change, condition of the highest and lowest mean and full
name of the protein are given in separate columns.
Accession Peptide
count
Unique
peptides
Confidence
score
Anova
(p)
Max fold
change
Highest
mean
condition
Lowest
mean
condition
Description
Q9H497 2 2 10.7157 0.001182 8.844932 Case Control Torsin-3A
P07339;C9JH19 2 2 11.8647 0.003668 2.631503 Case Control Cathepsin D
Q96SN7;C9J2H9;C9J5L2;
C9JQR7;C9JUY6
4 3 27.6575 0.000649 2.027496 Case Control Protein orai-2
Q9Y4B5;J3QLE1 3 2 20.227 0.010045 1.870043 Case Control Microtubule cross-linking
factor 1
Q08AH1;E5RFK0 3 3 18.8377 0.019465 1.84317 Case Control Acyl-coenzyme A
synthetase ACSM1,
mitochondrial
A0A087WU16;B2REA4;O75626 4 4 26.6581 7.38E-07 1.77715 Case Control PR domain zinc finger
protein 1
Q16531 2 2 7.7408 0.034509 1.750108 Case Control DNA damage-binding
protein 1
P02750 40 37 186.9309 0.00229 1.640414 Case Control Leucine-rich alpha-
2-glycoprotein
A0A0A0MTD1;A0A0A0MTC4;
A0A0A0MTC5;A0A0A0MTC6;
E5RJN7;E7EPX0;E7EVJ4;
E9PH62;F8VPI7;G5EA18;
Q9NUL3
5 4 22.6587 0.013193 1.61796 Case Control Double-stranded RNA-
binding protein Staufen
homolog 2
P04217;M0R009 48 41 261.3448 0.001136 1.596944 Case Control Alpha-1B-glycoprotein
O94782;C9JC88;C9JWX4 3 2 16.0733 0.001325 5.967845 Control Case Ubiquitin carboxyl-
terminal hydrolase 1
G3V1N2;P69905 3 3 31.698 0.000981 5.127688 Control Case HCG1745306, isoform
CRA_a
A0A075B702 2 2 17.6117 1.07E-05 4.41976 Control Case Protein TRAJ41
(Fragment)
E9PLW5;R4GN25 2 2 10.7804 0.003909 4.260173 Control Case Putative protein N-
methyltransferase
FAM86B1
P38935 2 2 9.2636 0.001711 3.612221 Control Case DNA-binding protein
SMUBP-2
O60309 4 3 18.0095 0.000957 3.304585 Control Case Leucine-rich repeat-
containing protein 37A3
E9PPB4 2 2 18.3488 0.002286 3.190066 Control Case Peroxisomal biogenesis
factor 19
Q7Z3I0;A0A075B7G4;Q8IYB9 3 2 22.3658 0.000508 3.14666 Control Case Putative uncharacterized
protein
DKFZp313E1411
H0YFH1 9 2 78.0417 0.005951 2.729399 Control Case Alpha-2-macroglobulin
(Fragment)
P01617;A0A0A0MTQ6 4 2 37.2069 6.15E-05 2.570449 Control Case Ig kappa chain V-II
region TEW
doi:10.1371/journal.pone.0172987.t001
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spread but separately from the controls. PCA can separate the two classes in Fig 1A. When
PCA was performed with proteins already different between the two classes (FC>2 and
ANOVA p value<0.05) the separation was even stronger.
3.4 Orthogonal Projections to Latent Structures Discriminant Analysis
(OPLS-DA)
OPLS-DA is a statistical modeling technique which models the data from two classes and pres-
ents the differences between the two groups. An S-Plot can be generated which allows for fea-
ture selection from the classes which are significantly different among the two groups and can
classify them. On the S-Plot, X-axis is the magnitude of change in a particular analyte and Y-
axis is the significance of the analyte in comparison of two groups. It can find the predictive
and uncorrelated variance in two group comparisons [21]. S-Plot generated for the current
study is given in Fig 2. Protein passing the cutoff value of +0.7 or -0.7 for p(corr) values were
considered significantly different between the two classes. The proteins passing the cutoff of p
(Corr) value higher or lower than 0.7 or -0.7 are presented in Table 2.
Fig 1. Principal component analysis of the proteomic dataset. Principal component analysis is presented in the figure where purple dots are the
controls and blue dots are the cases. The upper panel is when all the proteins with two or more unique peptides were considered for the PCA and lower
panel shows the PCA when only the proteins passing the cutoff of ANOVA p value less than 0.05 were considered for PCA. Only one of the triplicate runs
are shown in the PCA.
doi:10.1371/journal.pone.0172987.g001
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3.5 Pathway analysis
We used two different tools for pathway analysis namely Integrated Molecular Pathway Level
Analysis (IMPaLA)[20] and Ingenuity pathway analysis (IPA). Pathway overrepresentation
analysis was performed using IMPaLA and the results are summarized in Fig 3. When the
highest mean was set to controls, only two pathways passed the cutoff (Q_genes of 0.05) which
can be seen in the right panel. These pathways were mainly related to scavenger receptors. In
the highest mean case condition, several pathways passed this cutoff and top 5 pathways are
shown in the Fig 3 left panel. In this category, platelet degranulation and complement and
coagulation cascades were the main categories to which most pathways were related. Comple-
ment activation will be expected to be overactive in a sepsis like situation and these pathways
point towards that phenomenon. All the pathway enrichment results are given in S2 Table.
Pathway analysis was also performed with IPA tool and several canonical pathways and
molecular and cellular functions as well as physiological system development functions as well
as networks were enriched in the dataset. Some of these pathways/networks relevant to our
study are presented here. Top disease and biofunctions enriched in the dataset are given in S3
Table. Metabolic disease and organismal injury or abnormality were the main category
enriched while lipid metabolism, immune response and hematological system development
were also enriched (S3 Table). It is to be noted that IMPaLA also enriched the immune
response and lipid transport as main categories (Fig 3). Canonical pathways enriched in the
current dataset are shown in the Fig 4. Note that only the top pathways are shown due to lack
of space in the figure. All the canonical pathways enriched are given in the S4 Table. The
canonical pathways in Fig 4 are sorted down to decreasing–log (p value) of enrichment. Note
that this p value is corrected for multiple testing (B-H p value). Some of the pathways signifi-
cant enriched pathways were acute phase response signaling, clathrin-mediated endocytosis,
coagulation system and IL-12 signaling.
Fig 2. OPLS-DA modeling associated S-Plot. S-plot of the cases with a positive blood culture versus blood
culture negative controls: S–Plot obtained from OPLS-DA regression analysis is shown here. Variables
having a p(corr) value higher than 0.7 or lower than -0.7 are considered significantly different which can
perform class separation between cases and controls. Upper right portions are the proteins downregulated
and lower left portion are the proteins upregulated in plasma of patients with a bloodstream infection. Data are
log10 transformed and mean centered.
doi:10.1371/journal.pone.0172987.g002
Plasma protein profile changes in bloodstream infection
PLOS ONE | DOI:10.1371/journal.pone.0172987 February 24, 2017 8 / 17
3.6 ROC curve analysis
Proteins selected by S-Plot, as being most significantly different among the two classes of sam-
ples (cases vs controls), were further analyzed by ROC curve analysis. Area under the curve
(AUC) and optimal cutoff with cost values were calculated which are shown in Table 3. ROC
curve is a binary classification technique and it can numerically suggest the better classifiers
for two groups among the classifiers analyzed (by AUC values). The program named Analyse-
it, was used for calculating these values with default options. These calculations serve as
Table 2. Proteins significantly different in the S-Plot in cases versus controls are shown in the table. Uniprot accession or a group of accessions is
given as primary Id. Peptides column represents the total number of peptides found for the said protein and unique peptides are number of unique peptides
out of the total peptides for the given protein. Confidence score, ANOVA p value, highest and lowest mean condition, full name of the protein, covariance (p[1])
and correlation (p(corr)[1]) are given in various columns of the table.
Primary
accession
All
peptides
Unique
peptides
Confidence
score
ANOVA
p-value
Fold
change
Highest
mean
Lowest
mean
Description p[1] p
(corr)
[1]
A0A075B702 2 2 17.6 1.07E-05 4.4 Control Case Protein TRAJ41 (Fragment)
OS = Homo sapiens GN = TRAJ41
PE = 4 SV = 1
0.03 0.81
E9PLW5;
R4GN25
2 2 10.8 3.91E-03 4.3 Control Case Putative protein N-
methyltransferase FAM86B1
OS = Homo sapiens
GN = FAM86B1 PE = 4 SV = 1
0.02 0.80
P01617;
A0A0A0MTQ6
4 2 37.2 6.15E-05 2.6 Control Case Ig kappa chain V-II region TEW
OS = Homo sapiens PE = 1 SV = 1
0.04 0.79
Q8IU89;
H0YMG6;
H0YN05
4 4 31.0 3.96E-04 1.9 Control Case Ceramide synthase 3 OS = Homo
sapiens GN = CERS3 PE = 1
SV = 2
0.03 0.79
P38935 2 2 9.3 1.71E-03 3.6 Control Case DNA-binding protein SMUBP-2
OS = Homo sapiens
GN = IGHMBP2 PE = 1 SV = 3
0.02 0.77
Q7Z3I0;
A0A075B7G4;
Q8IYB9
3 2 22.4 5.08E-04 3.1 Control Case Putative uncharacterized protein
DKFZp313E1411 OS = Homo
sapiens GN = DKFZp313E1411
PE = 2 SV = 1
0.03 0.76
O94782;
C9JC88;
C9JWX4
3 2 16.1 1.33E-03 6.0 Control Case Ubiquitin carboxyl-terminal
hydrolase 1 OS = Homo sapiens
GN = USP1 PE = 1 SV = 1
0.02 0.74
Q7RTY7;
H0YGY6;
H0YH00
6 3 37.5 2.47E-03 2.3 Control Case Ovochymase-1 OS = Homo
sapiens GN = OVCH1 PE = 2
SV = 2
0.03 0.73
E7EVV8;
Q0VG06
2 2 10.9 1.17E-03 1.8 Control Case Fanconi anemia-associated
protein of 100 kDa OS = Homo
sapiens GN = FAAP100 PE = 1
SV = 1
0.03 0.70
P02763 48 38 239.3 6.49E-03 1.6 Case Control Alpha-1-acid glycoprotein 1
OS = Homo sapiens GN = ORM1
PE = 1 SV = 1
-0.30 -0.71
P07339;C9JH19 2 2 11.9 3.67E-03 2.6 Case Control Cathepsin D OS = Homo sapiens
GN = CTSD PE = 1 SV = 1
-0.06 -0.72
P04217;M0R009 48 41 261.3 1.14E-03 1.6 Case Control Alpha-1B-glycoprotein OS = Homo
sapiens GN = A1BG PE = 1 SV = 4
-0.23 -0.75
P02750 40 37 186.9 2.29E-03 1.6 Case Control Leucine-rich alpha-2-glycoprotein
OS = Homo sapiens GN = LRG1
PE = 1 SV = 2
-0.23 -0.77
A0A087WU16;
B2REA4;
O75626
4 4 26.7 7.38E-07 1.8 Case Control PR domain zinc finger protein 1
OS = Homo sapiens GN = PRDM1
PE = 1 SV = 1
-0.04 -0.81
doi:10.1371/journal.pone.0172987.t002
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validations of the OPLS-DA model and further suggest which proteins selected by S-Plot also
acts as classifiers in ROC curve analysis. One out of the fourteen proteins had the AUC value
of 1 and the other eight proteins had the AUC values of 0.90 to 0.99.
4. Discussion
Blood culture is currently the gold standard for diagnosing the bloodstream infections. It
depends on detecting live microbes in the blood by culturing techniques and many microbes
may not be cultivated by the currently used techniques at all. However, even in the best scenar-
ios, the results of the culture are seldom available before 12 hours and in clinical practice much
later than that. In most severe cases, after the onset of hypotension in septic shock, every
hour’s delay in onset of antibiotic treatment is associated with decreased survival by about 8%
[22]. Blood volume used for the culture, time from sampling to incubation, slow-growing
microorganisms and ongoing antimicrobial therapy are among some of the factors which
influence and reduce the sensitivity of the blood culture [23–29]. There is an increasing need
for biomarkers which give an idea of presence of bacterial pathogens in blood stream and type
of them even before the blood cultures reports have come-in to aid the clinicians early.
C-reactive protein (CRP) and procalcitonin (PCT) are among the current most promising
biomarkers of sepsis. However, CRP for example is increased in several other conditions such
as myocardial infarction and trauma [30] and rheumatologic diseases [31]. Non-specific
dynamics of CRP don’t support its use as diagnostic biomarker of sepsis. PCT, on the other
hand is more specific and several studies demonstrate its elevation in sepsis [32–34]. However,
there is controversy regarding its clinical usefulness. A meta-analysis has suggested that PCT
cannot differentiate bloodstream infection from other causes of systemic inflammatory
Fig 3. Pathway over-representation analysis by IMPaLA. Pathway enrichment analysis using IMPaLA web based server was performed on two
proteins list, one having highest mean in controls (left panel) and other having highest mean in case (blood culture positive). P-values are given in blue
bars while Q values are represented by red bars.
doi:10.1371/journal.pone.0172987.g003
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response [35]. The lack of appropriate biomarkers to aid in the diagnosis of bloodstream infec-
tion calls for more studies to find appropriate biomarkers.
We have performed a pilot study of ten individuals with confirmed blood culture positivity
due to various bacteria. Ten age and sex-matched febrile blood culture-negative patients with
identical clinical indications for blood culture sampling have served as controls for quantitative
plasma proteomics profile. Abundant proteins such as albumin represent 99% of the total
plasma proteins and their removal increases the detection of low-abundant proteins which
might be clinically important [36]. After the depletion of albumin, we have quantified 172 pro-
teins after filtering to consider only the proteins with two or more unique peptides. These pro-
teins were used for PCA analysis of the samples and it was found that blood culture positive
and negative patients separated from each other on the PCA biplot space in two different clus-
ters. The separation was improved even more when only the proteins with FC>2 and ANOVA
p-value <0.05 were used for PCA. However, it is to be considered with caution that selecting
proteins already different among the two classes for PCA will always lead to better PCA out-
comes. Therefore, only the PCA with total proteins should be interpreted in terms of biological
meaning in a study.
Fig 4. Canonical pathways found by core analysis in IPA. Ingenuity Pathway Analysis “Core analysis” enriched top canonical pathways are shown
here. Straight orange vertical line running through the bars is threshold for p value for the particular pathway’s enrichment. Horizontal axis is the–log (p
value) and vertical axis represents the given pathways.
doi:10.1371/journal.pone.0172987.g004
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OPLS-DA modeling and subsequent S-Plot generated the proteins which have the predic-
tive variance for the classes. Only the proteins with the threshold of 0.7 for p(corr) were con-
sidered significantly different (Table 2). Among these proteins, was found ceramide synthase
3. One of the family members of this class of protein ceramide sythnase 2 is implicated in sep-
sis like injury. Cearmide sythnase 2 null mouse die within 10 hr subsequent to injections of
high doses of lipopolysaccahrides [37]. Kappa light chains are also previously known to be dif-
ferentially expressed in different stages of sepsis [38]. However, they have also been implicated
in some viral infections such as HIV-1 [39]. They are likely part of the host response during
infection and inflammation [40]. Their downregulation in bloodstream infection patients, as
found in our dataset (Table 2) represent cases where prognosis might be difficult. Another
S-Plot-significant protein found to be downregulated in blood stream infection patients in our
dataset was Ubiquitin carboxyl-terminal hydrolase 1 (USP-1). Ubiquitination machinery, par-
ticularly ubiquitin ligases, is known to be upregulated in sepsis patients [41]. Therefore it
makes sense that in infected patients ubiquitin hydrolase was found to be downregulated in
our dataset. Other types of proteases such as serine proteases also play important role in host
response against bacteremia [42]. In line with this fact, another S-Plot-significant protein, ovo-
chymase-1 (Table 2) was found to be downregulated in bloodstream infection patients in our
dataset. In general, downregulation of host response proteins is a salient feature of blood-
stream infection proteins with several examples present in our dataset and that of others.
Among proteins, which are upregulated in bloodstream infected patients in our dataset is
alpha-1-acid glycoprotein 1 (AGP). This protein is frequently found to be lower in expression
in patients which develop septic shock [43]. Patients involved in our study had not reach that
stage by the time of sampling therefore, it makes sense that AGP levels were still high. On the
other hand, high levels of AGP do not confer any advantages on host and they are deleterious
to the survival. It is known that in infected mice (murine model of sepsis), administration of
AGP can block the migration of neutrophils to the site of infection, thus increasing mortality
[44]. Another upregulated protein in infected patients in our dataset was PR domain zinc fin-
ger protein 1 (PRDM1). This protein downregulates the CCL8 which makes the host suscepti-
ble to bacterial infections compared to individuals having normal levels of CCL8 [45]. A story
Table 3. Proteins found to be significantly different in S-Plot were analyzed by ROC curve by Analyse-it program. Uniprot accession, full protein
name (description), Area under the curve (AUC), 95% confidence interval (95% CI), standard error (SE), optimum threshold, sensitivity at that threshold and
1-specificity at that threshold and cost for the optimum threshold are shown in the table in various columns.
Primary accession Description AUC 95% CI SE
A0A075B702 Protein TRAJ41 (Fragment) 0.98 0.933 to 1.027 0.02
E9PLW5;R4GN25 Putative protein N-methyltransferase FAM86B1 1.00 1 to 1 0.00
P01617;A0A0A0MTQ6 Ig kappa chain V-II region TEW 0.96 0.886 to 1.034 0.04
Q8IU89;H0YMG6;H0YN05 Ceramide synthase 3 0.94 0.818 to 1.062 0.06
P38935 DNA-binding protein SMUBP-2 0.97 0.911 to 1.029 0.03
Q7Z3I0;A0A075B7G4;Q8IYB9 Putative uncharacterized protein DKFZp313E1411 0.98 0.933 to 1.027 0.02
O94782;C9JC88;C9JWX4 Ubiquitin carboxyl-terminal hydrolase 1 0.97 0.911 to 1.029 0.03
Q7RTY7;H0YGY6;H0YH00 Ovochymase-1 0.87 0.712 to 1.028 0.08
E7EVV8;Q0VG06 Fanconi anemia-associated protein of 100 kDa 0.90 0.748 to 1.052 0.08
P02763 Alpha-1-acid glycoprotein 1 0.83 0.645 to 1.015 0.09
P07339;C9JH19 Cathepsin D 0.89 0.694 to 1.086 0.10
P04217;M0R009 Alpha-1B-glycoprotein 0.85 0.666 to 1.034 0.09
P02750 Leucine-rich alpha-2-glycoprotein 0.86 0.696 to 1.024 0.08
A0A087WU16;B2REA4;O75626 PR domain zinc finger protein 1 0.99 0.962 to 1.018 0.01
doi:10.1371/journal.pone.0172987.t003
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emerges from our results containing several examples that host response to infection is
extremely important and can dictate the survival of infected individuals. Furthermore, host
response, as exemplified by lower or higher expression of its component proteins, is dysregu-
lated in bloodstream infected patients compared to other individuals. These individuals pres-
ent with fever but remain clearly lower in evolution of infectious disease, not reaching at the
level of bloodstream infection at the time of blood sampling. It can be contemplated here that
host response is the main differentiating factor between these two groups which is bloodstream
infected (group 1) and otherwise febrile patients (group 2). It might be possible to postulate
here, that keeping in mind the sensitivity of the blood culture technique, blood based protein
biomarkers can be a better indicator of infection status of patients presenting febrile symptoms
at the hospital emergency site. At the same time, plasma proteomics combined with statistical
analysis can delineate the pathways involved in blood stream infections and make a case for
therapeutic target identification in future studies.
Coming to pathways, lipid metabolism and transport was the main molecular and cellu-
lar function found by IPA and activation of scavenger receptors was the main overrepre-
sented pathways in the control patients. Complement and coagulation systems pathways
were mainly enriched in the case’s proteomic dataset. LXR/RXR activation was one of the
pathways enriched in both the IPA and IMPaLA analysis and this pathway is indirectly
related to the activation of lipid metabolism and transport. Lipid metabolism was also one
of the top molecular and biofunctions in IPA analysis. Altered lipid metabolism has been
previously reported in sepsis [46] which is also reflected in our study. Complement and
coagulation pathways, on the other hand, are much more obvious and would be expected to
be activated upon infection.
The 14 proteins suggested by S-Plot are the high-confidence target biomarkers which can
potentially classify patients with a bloodstream infection from blood culture negative control
patients. These proteins were further analyzed by ROC curve to validate their predictive power
to classify the disease versus healthy control samples. It was noted that, mostly, lower AUC
value proteins also had lower p(corr) values. Therefore, these two techniques can prove to be
complementary to each other.
In conclusion, we observed clear changes in plasma proteomics among documented blood
culture positive patients as compared to blood culture negative patients in this pilot study.
These findings seemed not to depend on bacterial species as various different bacteria were
found in blood culture positive patients. Among the blood culture negative patients we had a
set of real life patients with clear bacterial infections, less clear infectious conditions and clearly
patients without any infection and they all differed in their plasma proteomic findings from
bacteremic (Bloodstream infected and blood culture positive) patients. These findings encour-
age further studies to confirm the results in large patient groups and different clinical back-
ground. One hope could be that future studies could point out one or more proteins that
might be universally differentiated between groups and could be subjected to further develop-
ment of clinically exploitable and feasible test(s).
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